AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
ST
Scribe TherapeuticsClinical-stage biotech developing CRISPR-based gene-editing therapeutics using its proprietary CasX enzyme platform.
5 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
Attovia TherapeuticsScribe Therapeutics
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
Attovia TherapeuticsScribe Therapeutics
Biotech
Sector
Biotech
2023
Founded
2018
San Carlos, CA
HQ
Alameda, California
Public (ATTO)
Status
Public (SCTX)
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Scribe Therapeutics investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and Scribe Therapeutics.